Literature DB >> 23403742

Metabolic surgery for type 2 diabetes: efficacy and risks.

Florencia Halperin1, Allison B Goldfine.   

Abstract

PURPOSE OF REVIEW: Bariatric surgery has emerged as a highly effective treatment for obesity and is increasingly recognized to have benefits for glycemic management in patients with pre-existing type 2 diabetes mellitus (T2DM), and for diabetes prevention. This article will review the efficacy and mechanisms of metabolic surgery for the treatment of T2DM. RECENT
FINDINGS: Recent small randomized studies with 1-2 years of follow-up begin to provide level 1 data of the effects of surgical procedures compared to medical management on glycemic control. Physiology studies using sophisticated metabolic techniques to evaluate insulin secretion, action, and entero-endocrine changes in patients preoperatively and postoperatively have shed light on the mechanisms that lead to changes in glycemia observed after bariatric surgery.
SUMMARY: Understanding the efficacy and physiologic effects of bariatric surgery on metabolism will help guide patient management in the context of a growing epidemic of obesity and T2DM, and may also ultimately enable us to develop less invasive but equally effective therapeutic strategies for weight loss and metabolic control.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403742     DOI: 10.1097/MED.0b013e32835edbb0

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  3 in total

1.  Impact of Bariatric Surgery on Patients With Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Florencia Halperin; Jonathan C Karlson; Elizabeth W Karlson; Bonnie L Bermas
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-12       Impact factor: 4.794

Review 2.  The Bariatric Patient in the Intensive Care Unit: Pitfalls and Management.

Authors:  Carlos E Pompilio; Paolo Pelosi; Melina G Castro
Journal:  Curr Atheroscler Rep       Date:  2016-09       Impact factor: 5.113

3.  Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus.

Authors:  Ren Wang; Lihua Dai; Jinjin Chen
Journal:  Exp Ther Med       Date:  2014-12-01       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.